Novo Nordisk + OpenAI
Novo Nordisk announced a broad partnership with OpenAI to apply AI across drug discovery, manufacturing, distribution and commercial operations. (reuters.com) The company said it will roll the tools out globally and upskill staff, and reporting notes Novo has fallen behind Eli Lilly in the weight‑loss drug market. (cnbc.com)
Novo Nordisk said Tuesday it is partnering with OpenAI to use artificial intelligence across drug research, factories, supply chains and sales operations. (biospace.com) The Danish drugmaker said OpenAI’s tools will be rolled out globally, starting with pilot programs in research and development, manufacturing and commercial teams, with full integration planned by the end of 2026. (biospace.com) Novo said the software will be used to analyze large datasets, spot possible drug candidates and shorten the path from lab work to patient use, while also helping with manufacturing, distribution and corporate operations. (cnbc.com) Drugmakers have been testing artificial intelligence as a way to sift through huge volumes of biology and trial data, but consultants and executives still describe the nearer-term gains as faster research workflows, better trial design and lower operating costs. (cnbc.com) Novo is making the move after a difficult stretch in obesity drugs. CNBC reported in February that Eli Lilly had taken a clear edge in market share in obesity and diabetes medicines, while Novo was trying to win back ground in the United States. (cnbc.com) Novo’s own 2025 annual report said it remained the global branded obesity market leader by volume with a 59.6% share, even as it warned of intensifying competition in 2026 and said it was expanding Wegovy launches and higher doses in more countries. (annualreport.novonordisk.com) The company has already been building out artificial intelligence partnerships. Bloomberg reported that the OpenAI deal adds to a research-focused collaboration with Nvidia announced last year. (bloomberg.com) Investors initially welcomed the announcement. Novo shares rose 2.8% shortly after the opening bell on April 14, according to CNBC. (cnbc.com) Novo said OpenAI will also help train its workforce in artificial intelligence literacy, with the company keeping human oversight and data-governance controls around the systems as it pushes the tools into everyday work. (biospace.com)
